HCA Healthcare Stock Underperforms Amid Weak Q1 EBITDA Results
HCA Healthcare (HCA) has underperformed the broader market over the past 52 weeks and on a year-to-date basis. The stock dropped 8.8% after reporting weaker-than-expected adjusted EBITDA of $3.80 billion for Q1 2026, despite revenue rising to $19.1 billion.
Topics: earnings report healthcare market performance stocks